Herantis Pharma will attend Bio-Europe 2022 and Redeye Neurology Day
Herantis Pharma Plc, Press Release, 5 October 2022 at 15:30 EEST
Herantis Pharma Plc (“Herantis”), developing disease modifying therapies for Parkinson’s disease, today announced that CEO Antti Vuolanto and CSO Henri Huttunen will be attending and holding 1x1 meetings at Bio-Europe 2022 between October 24th–26th, 2022. Additionally, CEO Antti Vuolanto will be attending, presenting, and participating in a CNS panel discussion at Redeyes’ Theme: Neurology Day on October 12th, 2022.
Conference Details:
Redeye Theme: Neurology
Date: October 12th, 2022
Webcast Link: Live Broadcast
Bio-Europe 2022
Dates: October 24–26, 2022
Location: Leipzig, Germany
If you are interested in scheduling a 1x1 meeting with Herantis management you can contact the conference organizers, connect with us via the Bio-Europe 1x1 platform, and/or send an email to ir@herantis.com.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: ir@herantis.com
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information, please visit www.herantis.com.